Please select the option that best describes you:
What is your preferred adjuvant systemic treatment for resected stage IV melanoma with a BRAF mutation?
Based on available results from the IMMUNED trial, which evaluated the role of adjuvant nivolumab/ipilimumab or nivolumab monotherapy vs placebo in resected stage IV melanoma, would you still consider BRAF/MEK targeted therapy as an option?
Answer from: Medical Oncologist at Academic Institution
I agree with @Claire F. Verschraegen and prefer single-agent anti-PD1 therapy for adjuvant setting as well, given better tolerance and preserved QoL for most patients. I use targeted therapy in contraindications to ICI therapy, or prior exposure to ICI, and now with resected NED setting.
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Unless there is a contraindication to immunotherapy, I would recommend the standard of care single agent PD1 inhibitor. If there is a contraindication, BRAF inhibitors are the drugs of choice.